Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
65162-0804-51 65162-0804 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Apr 3, 2015 In Use
12634-0188-85 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 26, 1974 In Use
66267-0067-12 66267-0067 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 28, 2016 Dec 31, 2018 In Use
70771-1185-03 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan 3, 2018 In Use
42023-0238-01 42023-0238 METHYLPREDNISOLONE ACETATE METHYLPREDNISOLONE ACETATE 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, INTRAMENINGEAL, Soft Tissue, Intramuscular Nov 2, 2023 In Use
16729-0295-34 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sep 19, 2017 In Use
51862-0084-51 51862-0084 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct 10, 2016 Mar 31, 2019 In Use
00004-0350-09 00004-0350 Peginterferon alfa-2a Pegasys 180.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Oct 16, 2002 Jun 30, 2025 In Use
21695-0306-39 21695-0306 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Dec 4, 1985 In Use
40051-0608-13 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
45963-0500-30 45963-0500 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Mar 28, 2007 Jul 31, 2019 In Use
60505-3803-07 60505-3803 Nilotinib Nilotinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
71288-0107-20 71288-0107 Bleomycin Sulfate Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Aug 31, 2018 In Use
00527-1726-40 00527-1726 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Jul 1, 2010 In Use
45963-0607-55 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Mar 1, 2015 In Use
00006-4119-01 00006-4119 Human Papillomavirus 9-valent Vaccine, Recombinant GARDASIL 9 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL Ancillary Therapy Protective Agent HPV Vaccine Intramuscular Dec 10, 2014 In Use
00555-0484-02 00555-0484 Leucovorin Calcium Leucovorin Calcium 5.0 mg/1 Ancillary Therapy Chemoprotective Antidote Oral Jun 30, 1990 In Use
72485-0203-30 72485-0203 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 15, 2019 In Use
00024-0654-01 00024-0654 Isatuximab Sarclisa 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Mar 2, 2020 In Use
60219-1706-03 60219-1706 prednisone prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 4, 2021 In Use
49999-0109-00 49999-0109 conjugated estrogens Premarin 0.625 mg/1 Hormonal Therapy Estrogen Oral Mar 21, 2012 Jan 1, 2013 In Use
63187-0709-15 63187-0709 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 1, 2016 In Use
00143-9744-01 00143-9744 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec 23, 2009 In Use
00574-0870-05 00574-0870 Estradiol Valerate Estradiol Valerate 20.0 mg/mL Hormonal Therapy Estrogen Intramuscular Mar 31, 2010 In Use
50881-0013-01 50881-0013 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug 5, 2020 Jan 30, 2025 In Use

Found 11564 results — Export these results